RxDoctor Payments Data

Jorge Mestas, MD

Pulmonary Disease · Fort Myers, FLNPI 1467450494

Payments from drug & device makers

$21,262in general payments, 2019–2025

Across 556 payments — averaging $38.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$10K
  • AstraZeneca$2K
  • GSK$2K
  • Boehringer Ingelheim$758
  • Regeneron Healthcare Solutions, Inc.$593
  • Insmed, Inc.$522
  • plus $5K from 47 others

What the payments were for

  • Travel & lodging$1,1335%
  • Food & beverage$11,00152%
  • Education$9,12843%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,262 in reported general payments places this provider in the 75th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$204,355
Medicare patients
725
Services billed
2,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter283$321,007
OfevNintedanib Esylate21$278,881
TezspireTezepelumab-Ekko25$108,237
SymbicortBudesonide/Formoterol Fumarate331$98,651
Theophylline ErTheophylline Anhydrous1,164$83,641
Breztri AerosphereBudesonide/Glycopyr/Formoterol66$67,030
Breo ElliptaFluticasone/Vilanterol67$45,967
Fluticasone-SalmeterolFluticasone Propion/Salmeterol181$29,793
EliquisApixaban34$28,216
XareltoRivaroxaban15$18,825
Pirfenidone16$13,460
BreynaBudesonide/Formoterol Fumarate74$13,044
Wixela InhubFluticasone Propion/Salmeterol96$10,908
Misoprostol308$10,259
Albuterol Sulfate HfaAlbuterol Sulfate313$8,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$2,096$366,974350 claims
Boehringer IngelheimOfev$758$278,88121 claims
AstraZenecaTezspire, Symbicort, Breztri Aerosphere$2,313$273,918422 claims
Johnson & JohnsonXarelto$91$18,82515 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$71$1,246129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →